Genetic susceptibility to temporomandibular joint involvement in juvenile idiopathic arthritis.
craniofacial growth disturbances
genome‐wide association study
juvenile idiopathic arthritis
rheumatoid arthritis
temporomandibular joint
Journal
Journal of oral rehabilitation
ISSN: 1365-2842
Titre abrégé: J Oral Rehabil
Pays: England
ID NLM: 0433604
Informations de publication
Date de publication:
27 Aug 2024
27 Aug 2024
Historique:
revised:
17
12
2023
received:
28
03
2023
accepted:
01
08
2024
medline:
28
8
2024
pubmed:
28
8
2024
entrez:
28
8
2024
Statut:
aheadofprint
Résumé
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic condition of childhood. Temporomandibular joint (TMJ) is among the most commonly affected joints in JIA patients. When JIA involves the TMJ, it may affect condylar growth in the joint; therefore, JIA patients are at risk of unfavourable long-term outcomes from associated joint damage. If undetected, TMJ involvement can lead to various functional disabilities such as reduced mandibular mobility and disorders of the mastication muscles. Limitations in sagittal and vertical mandibular growth can result in micrognathia and anterior open bite with aesthetic and functional restrictions. Genetic factors may play a role in determining which individuals are more prone to develop TMJ disorders or in predicting the severity of the disease process. Therefore, we applied a GWAS approach to identify loci associated with TMJ involvement in a sample of Estonian patients with JIA. Our aim was to address the potential role of genetic susceptibility factors in TMJ-JIA, a condition not previously studied in this context. The case group consisted of 55 JIA patients with TMJ involvement and 208 patients without TMJ involvement comprised the control group. The entire cohort was genotyped using the Illumina HumanOmniExpress BeadChip arrays. Imputation was performed using a nationwide reference panel obtained of 2240 individuals whose data were obtained from the Estonian Biobank. We identified six loci as being associated with the risk of TMJ-JIA in Estonian JIA patients. The strongest associations were identified at CD6 rs3019551 (P = 3.80 × 10 This study provides first insights into the risk-associated loci between JIA and its manifestation in the TMJ. The reported loci are involved in molecular pathways of immunological relevance and likely represent genomic regions that render the TMJ susceptible to involvement by JIA in Estonian patients.
Sections du résumé
BACKGROUND
BACKGROUND
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic condition of childhood. Temporomandibular joint (TMJ) is among the most commonly affected joints in JIA patients. When JIA involves the TMJ, it may affect condylar growth in the joint; therefore, JIA patients are at risk of unfavourable long-term outcomes from associated joint damage. If undetected, TMJ involvement can lead to various functional disabilities such as reduced mandibular mobility and disorders of the mastication muscles. Limitations in sagittal and vertical mandibular growth can result in micrognathia and anterior open bite with aesthetic and functional restrictions.
OBJECTIVE
OBJECTIVE
Genetic factors may play a role in determining which individuals are more prone to develop TMJ disorders or in predicting the severity of the disease process. Therefore, we applied a GWAS approach to identify loci associated with TMJ involvement in a sample of Estonian patients with JIA. Our aim was to address the potential role of genetic susceptibility factors in TMJ-JIA, a condition not previously studied in this context.
METHODS
METHODS
The case group consisted of 55 JIA patients with TMJ involvement and 208 patients without TMJ involvement comprised the control group. The entire cohort was genotyped using the Illumina HumanOmniExpress BeadChip arrays. Imputation was performed using a nationwide reference panel obtained of 2240 individuals whose data were obtained from the Estonian Biobank.
RESULTS
RESULTS
We identified six loci as being associated with the risk of TMJ-JIA in Estonian JIA patients. The strongest associations were identified at CD6 rs3019551 (P = 3.80 × 10
CONCLUSION
CONCLUSIONS
This study provides first insights into the risk-associated loci between JIA and its manifestation in the TMJ. The reported loci are involved in molecular pathways of immunological relevance and likely represent genomic regions that render the TMJ susceptible to involvement by JIA in Estonian patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Pruunsild C, Uibo K, Liivamägi H, Tarraste S, Talvik T, Pelkonen P. Prevalence and short‐term outcome of juvenile idiopathic arthritis: a population‐based study in Estonia. Clin Exp Rheumatol. 2007;25(4):649‐653.
Karhulahti T, Ylijoki H, Rönning O. Mandibular condyle lesions related to age at onset and subtypes of juvenile rheumatoid arthritis in 15‐year‐old children. Scand J Dent Res. 1993;101(5):332‐338. doi:10.1111/j.1600-0722.1993.tb01128.x
Cannizzaro E, Schroeder S, Müller LM, Kellenberger CJ, Saurenmann RK. Temporomandibular joint involvement in children with juvenile idiopathic arthritis. J Rheumatol. 2011;38(3):510‐515. doi:10.3899/jrheum.100325
Stoll ML, Kau CH, Waite PD, Cron RQ. Temporomandibular joint arthritis in juvenile idiopathic arthritis, now what? Pediatr Rheumatol Online J. 2018;16(1):32. doi:10.1186/s12969-018-0244-y
Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390‐392.
Voog Ü, Alstergren P, Eliasson S, Leibur E, Kallikorm R, Kopp S. Inflammatory mediators and radiographic changes in temporomandibular joints of patients with rheumatoid arthritis. Acta Odontol Scand. 2003;61(1):57‐64. doi:10.1080/ode.61.1.57.64
Morel M, Ruscitto A, Pylawka S, Reeve G, Embree MC. Extracellular matrix turnover and inflammation in chemically‐induced TMJ arthritis mouse models. PLoS One. 2019;14(10):e0223244. doi:10.1371/journal.pone.0223244
Hutami IR, Izawa T, Mino‐Oka A, et al. Fas/S1P1 crosstalk via NF‐κB activation in osteoclasts controls subchondral bone remodeling in murine TMJ arthritis. Biochem Biophys Res Commun. 2017;490(4):1274‐1281. doi:10.1016/j.bbrc.2017.07.006
Boyce BF. Advances in the regulation of osteoclasts and osteoclast functions. J Dent Res. 2013;92(10):860‐867. doi:10.1177/0022034513500306
Stoustrup P, Herlin T, Spiegel L, et al. Standardizing the clinical orofacial examination in juvenile idiopathic arthritis: an interdisciplinary, consensus‐based, short screening protocol. J Rheumatol. 2020;47(9):1397‐1404. doi:10.3899/jrheum.190661
Thouverey C, Caverzasio J. Focus on the p38 MAPK signaling pathway in bone development and maintenance. Bonekey Rep. 2015;4:711. doi:10.1038/bonekey.2015.80
Böhm C, Hayer S, Kilian A, et al. The alpha‐isoform of p38 MAPK specifically regulates arthritic bone loss. J Immunol. 2009;183(9):5938‐5947. doi:10.4049/jimmunol.0901026
Huang H, Ryu J, Ha J, et al. Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF‐ κ B transactivation by RANKL. Cell Death Differ. 2006;13(11):1879‐1891. doi:10.1038/sj.cdd.4401882
Matsumoto M, Kogawa M, Wada S, et al. Essential role of p38 mitogen‐activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem. 2004;279(44):45969‐45979. doi:10.1074/jbc.M408795200
Drexler SK, Kong PL, Wales J, Foxwell BM. Cell signalling in macrophages, the principal innate immune effector cells of rheumatoid arthritis. Arthritis Res Ther. 2008;10(5):216. doi:10.1186/ar2481
Guma M, Firestein GS. c‐Jun N‐terminal kinase in inflammation and rheumatic diseases. Open Rheumatol J. 2012;6:220‐231. doi:10.2174/1874312901206010220
Yoshizawa T, Hammaker D, Sweeney SE, Boyle DL, Firestein GS. Synoviocyte innate immune responses: I. Differential regulation of interferon responses and the JNK pathway by MAPK kinases. J Immunol. 2008;181(5):3252‐3258.
Lundberg AM, Drexler SK, Monaco C, et al. Key differences in TLR3/poly I:C signaling and cytokine induction by human primary cells: a phenomenon absent from murine cell systems. Blood. 2007;110(9):3245‐3252. doi:10.1182/blood-2007-02-072934
Nakano K, Boyle DL, Firestein GS. Regulation of DNA methylation in rheumatoid arthritis synoviocytes. J Immunol. 2013;190(3):1297‐1303. doi:10.4049/jimmunol.1202572
Umar S, Hedaya O, Singh AK, Ahmed S. Thymoquinone inhibits TNF‐α‐induced inflammation and cell adhesion in rheumatoid arthritis synovial fibroblasts by ASK1 regulation. Toxicol Appl Pharmacol. 2015;287(3):299‐305. doi:10.1016/j.taap.2015.06.017
Nygaard G, Di Paolo JA, Hammaker D, et al. Regulation and function of apoptosis signal‐regulating kinase 1 in rheumatoid arthritis. Biochem Pharmacol. 2018;151:282‐290. doi:10.1016/j.bcp.2018.01.041
Gantke T, Sriskantharajah S, Sadowski M, Ley SC. IκB kinase regulation of the TPL‐2/ERK MAPK pathway. Immunol Rev. 2012;246(1):168‐182. doi:10.1111/j.1600-065X.2012.01104.x
Senger K, Pham VC, Varfolomeev E, et al. The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation. Sci Signal. 2017;10(475):eaah4273. doi:10.1126/scisignal.aah4273
Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov. 2013;12(2):147‐168. doi:10.1038/nrd3930
Chowdhury FZ, Estrada LD, Murray S, Forman J, Farrar JD. Pharmacological inhibition of TPL2/MAP3K8 blocks human cytotoxic T lymphocyte effector functions. PLoS One. 2014;9(3):e92187. doi:10.1371/journal.pone.0092187
Li X, Acuff NV, Peeks AR, et al. Tumor progression locus 2 (Tpl2) activates the mammalian target of rapamycin (mTOR) pathway, inhibits Forkhead box P3 (FoxP3) expression, and limits regulatory T cell (Treg) immunosuppressive functions. J Biol Chem. 2016;291(32):16802‐16815. doi:10.1074/jbc.M116.718783
Alonso‐Ramirez R, Loisel S, Buors C, et al. Rationale for targeting CD6 as a treatment for autoimmune diseases. Arthritis. 2010;2010:130646. doi:10.1155/2010/130646
Orta‐Mascaró M, Consuegra‐Fernández M, Carreras E, et al. CD6 modulates thymocyte selection and peripheral T cell homeostasis. J Exp Med. 2016;213(8):1387‐1397. doi:10.1084/jem.20151785
Kofler DM, Farkas A, von Bergwelt‐Baildon M, Hafler DA. The link between CD6 and autoimmunity: genetic and cellular associations. Curr Drug Targets. 2016;17(6):651‐665. doi:10.2174/1389450117666160201105934
Enyindah‐Asonye G, Li Y, Ruth JH, et al. CD318 is a ligand for CD6. Proc Natl Acad Sci USA. 2017;114(33):E6912‐E6921. doi:10.1073/pnas.1704008114
Carrasco E, Escoda‐Ferran C, Climent N, et al. Human CD6 Down‐modulation following T‐cell activation compromises lymphocyte survival and proliferative responses. Front Immunol. 2017;8:769. doi:10.3389/fimmu.2017.00769
Arbore G, West EE, Spolski R, et al. T helper 1 immunity requires complement‐driven NLRP3 inflammasome activity in CD4+ T cells. Science. 2016;352(6292):aad1210. doi:10.1126/science.aad1210
Man SM, Kanneganti TD. Regulation of inflammasome activation. Immunol Rev. 2015;265(1):6‐21. doi:10.1111/imr.12296
Zhao C, Gu Y, Zeng X, Wang J. NLRP3 inflammasome regulates Th17 differentiation in rheumatoid arthritis. Clin Immunol. 2018;197:154‐160. doi:10.1016/j.clim.2018.09.007
Guo C, Fu R, Wang S, et al. NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis. Clin Exp Immunol. 2018;194(2):231‐243. doi:10.1111/cei.13167
Giancane G, Papa R, Vastert S, et al. Anakinra in patients with systemic juvenile idiopathic arthritis: long‐term safety from the Pharmachild registry. J Rheumatol. 2022;49(4):398‐407. doi:10.3899/jrheum.210563
Reiff A. Treatment of systemic juvenile idiopathic arthritis with tocilizumab—the role of anti‐Interleukin‐6 therapy after a decade of treatment. Biol Ther. 2012;2(1):1. doi:10.1007/s13554-012-0001-6
Spalinger MR, Lang S, Gottier C, et al. PTPN22 regulates NLRP3‐mediated IL1B secretion in an autophagy‐dependent manner. Autophagy. 2017;13(9):1590‐1601. doi:10.1080/15548627.2017.1341453
Xia ZB, Meng FR, Fang YX, et al. Inhibition of NF‐κB signaling pathway induces apoptosis and suppresses proliferation and angiogenesis of human fibroblast‐like synovial cells in rheumatoid arthritis. Medicine (Baltimore). 2018;97(23):e10920. doi:10.1097/MD.0000000000010920
Shen HH, Yang YX, Meng X, et al. NLRP3: a promising therapeutic target for autoimmune diseases. Autoimmun Rev. 2018;17(7):694‐702. doi:10.1016/j.autrev.2018.01.020